Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada

Published:2021-04-01 Issue:4 Volume:181 Page:499
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Meyers Daniel E.¹,Jenei Kristina²,Chisamore Timothy M.³,Gyawali Bishal⁴⁵⁶

Affiliation:

1. Department of Medicine, University of Calgary, Calgary, Alberta, Canada

2. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada

3. Leeds, Greenville and Lanark District Health Unit, Brockville, Ontario, Canada

4. Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Kingston, Ontario, Canada

5. Department of Oncology, Queen’s University, Kingston, Ontario, Canada

6. Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2776285/jamainternal_meyers_2021_oi_200112_1617393550.85881.pdf

Reference33 articles.

1. Examining trends in cost and clinical benefit of novel anticancer drugs over time.;Saluja;J Oncol Pract,2018

2. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.;Fojo;JAMA Otolaryngol Head Neck Surg,2014

3. An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials.;Kumar;JAMA Oncol,2016

4. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.;Kim;JAMA Intern Med,2015

5. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.;Davis;BMJ,2017

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10

2. Impact of competition on reimbursement decisions for cancer drugs in China: an observational study;The Lancet Regional Health - Western Pacific;2024-09

3. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis;The Lancet Oncology;2024-08

4. Uncertainty in Long-Term Relative Effectiveness of Medicines in Health Technology Assessment;Value in Health;2024-07

5. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS;Journal of Cancer Research and Clinical Oncology;2024-03-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3